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LETTERS TO EDITOR 
Concern has been raised on the recent High 
Court of Bombay ruling which stated that ECT 
without anesthesia was inhuman 
(Channabasavanna et al., 2000). Based on this 
the same authors have suggested the use of only 
modified ECT in clinical practice as patients may 
claim compensation for increasing the risk of 
complications while using unmodified ECT. 
However, the article by Andrade et al. (2000) 
provides new insights into the fact that 
unmodified ECT may have lesser complications 
than previously thought Hence, it is desirable 
that IPS frame guidelines, which consider both 
modified and unmodified ECT so that the 
psychiatrists practicing either modality of ECT 
in our country can be appropriately guided in 
legal issues. 
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FLUOXETINE AND PARESTHESIAS 
Sir, 
Paresthesia associated with selective 
serotonin reuptake inhibitor (SSRI) therapy is rare, 
and has been described both as an adverse effect 
of SSRI drugs (Masand and Gupta, 1999) and in 
part of the SSR'I withdrawal syndrome (Black et 
al., 2000) in Caucasian subjects. Since ethnic 
issues in psychopharmacology are an important 
matter, and since no case of paresthesia 
associated with SSRIs has so far been reported 
from the Indian subcontinent, we wish to place 
the following case on record, 
CASEREPORT 
Mrs. S, a 36-year-old woman, was 
prescribed fluoxetine (20 mg/day) for a DSM-IV 
diagnosis of adjustment disorder with depressed 
mood. A week later, she began to experience 
tingling sensations in the left foot. These 
paresthesias increased over the following weeks 
and spread to the entire lower limb and the left 
upper limb as well. 
Physical examination, hematocrit, blood 
glucose, serum electrolytes, thyroid function tests, 
spinal X-rays, and other investigations were a" 
within normal limits. She was antinuclear antibody 
negative. Medical, neurological, and orthopedic 
consultations ruled out identifiable disease. 
Fluoxetine was discontinued with the hypothesis 
that her symptoms were drug-related. There was 
a decrease in the intensity of the paresthesias. 
Withdrawal of fluoxetine, however, led to a 
worsening of mood. Fluoxetine was re-introduced. 
Resumption of the drug resulted in worsening of 
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the paresthesias. Fluoxetine was discontinued 
once again. Within ten days, all symptoms of 
paresthesia disappeared. 
DISCUSSION 
The temporal relationship of the paresthesia 
to fluoxetine therapy, and the appearance and 
disappearance of symptoms in association with 
the introduction and withdrawal of fluoxetine, 
indicate that the symptoms were likely to have 
been drug-induced. In this context, an interesting 
report documents that a women tolerated sertraline 
well, but developed paresthesias with fluoxetine 
(Bhatara et al., 1996). We conclude that 
medication should be considered as a possible 
cause if paresthesias develop in patients receiving 
SSRI drugs. As a final note, no literature describes 
the symptomatic differentiation of paresthesias 
due to SSRI therapy and paresthesias due to SSRI 
withdrawal. Etiological impressions therefore 
oepend upon whether the SSRI therapy is ongoing 
or being withdrawn. 
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